The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| DNA | +47.2% | N/A | N/A | -97% |
| S&P | +15.06% | +95.03% | +14.29% | +62% |
Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.
The company is forging ahead with next-generation drug development solutions.
Could this beaten-down stock turn things around in the near future?
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $49.60M | -11.7% |
| Gross Profit | $18.99M | -24.5% |
| Gross Margin | 38.28% | -6.5% |
| Market Cap | $624.73M | -2.3% |
| Market Cap / Employee | $0.75M | 0.0% |
| Employees | 834 | -31.5% |
| Net Income | -$60.30M | 72.2% |
| EBITDA | -$52.62M | 60.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $214.52M | -70.7% |
| Accounts Receivable | $23.13M | 24.4% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $428.83M | -5.2% |
| Short Term Debt | $0.00M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -22.07% | 23.8% |
| Return On Invested Capital | -71.86% | 6.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$40.29M | 63.8% |
| Operating Free Cash Flow | -$40.25M | 52.3% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.48 | 0.62 | 0.41 | 0.90 | 38.63% |
| Price to Sales | 1.95 | 2.33 | 1.30 | 2.67 | -28.26% |
| Price to Tangible Book Value | 0.54 | 0.68 | 0.46 | 1.01 | 35.42% |
| Enterprise Value to EBITDA | -7.32 | -4.99 | -3.10 | -10.67 | 249.52% |
| Return on Equity | -63.5% | -60.3% | -57.8% | -43.6% | -43.26% |
| Total Debt | $445.59M | $467.73M | $434.56M | $428.83M | -5.18% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
